Novel FAP-Targeted Heptamethine Cyanines for NIRF Imaging Applications
Fibroblast activation protein (FAP) is a pan-cancer target that is useful for imaging, ideally all epithelial cancers. This work aimed to develop, characterize, and validate two novel FAP-targeted probes for optical imaging, both in <i>vitro</i> and <i>in vivo</i>. IRDye800CW and FNIRTag heptamethine cyanines were conjugated to the NH precursor of the well-known FAP inhibitor FAPI-46, which is widely employed in nuclear medicine. In addition to synthesis, the dyes were characterized in terms of physicochemical properties, biodistribution, and imaging performances in a breast cancer tumor model. FAPI-FNIRTag showed a stronger fluorescence and higher photostability compared to FAPI-IRDye800CW. Notably, both compounds exhibited strong tumor accumulation in TUBO breast cancer-bearing mice 24 h postadministration, suggesting potential for further investigation as fluorescence-guided surgery (FGS) agents.
Authors
- Enzo Terreno (ORCID: https://orcid.org/0000-0003-3800-566X)
- Valeria Poli (ORCID: https://orcid.org/0000-0002-3739-3966)
- Laura Conti (ORCID: https://orcid.org/0000-0003-1780-098X)
- Lidia Avalle (ORCID: https://orcid.org/0000-0002-5060-633X)
- Rebecca Rizzo (ORCID: https://orcid.org/0000-0002-8810-110X)
- Martina Capozza
Institutions
- Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
- University of Turin (IT)
Publication Details
- Journal
- Molecular Pharmaceutics
- Published
- 2025-02-15
- DOI
- https://doi.org/10.1021/acs.molpharmaceut.4c01232
- Citations
- 6
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 6.27